Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054734 | 0.75 | GAA (0.37) | UHRF1OR51E2 | |
| SCHEMBL19153846 | 0.73 | PARP1 (0.43) | UHRF1OR51E2DYRK1A | |
| SCHEMBL31567328 | 0.69 | HCAR2 (0.56) | — | |
| SCHEMBL19153117 | 0.69 | PARP1 (0.49) | — | |
| SCHEMBL12361762 | 0.67 | HCAR2 (0.48) | — | |
| SCHEMBL12094375 | 0.67 | — | — | |
| SCHEMBL19153741 | 0.67 | HPGD (0.33) | UHRF1OR51E2DYRK1A | |
| SCHEMBL19153334 | 0.65 | CRBN (0.39) | — | |
| SCHEMBL20674140 | 0.65 | TSHR (0.50) | — | |
| SCHEMBL27380094 | 0.65 | TSHR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | UHRF1 2152/4885OR51E2 1865/4885DYRK1A 1107/4885 |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | UHRF1 3637/4885OR51E2 4340/4885DYRK1A 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.